Nanordica Medical

Nanordica Medical is an Estonian medtech company founded in 2019, emerging from the National Institute of Chemical Physics and Biophysics. The company specializes in advanced antibacterial wound care products aimed at improving wound management and reducing healthcare costs for patients with chronic wounds, such as diabetic foot ulcers and pressure ulcers. Their flagship product is an advanced antibacterial wound dressing that combines copper and silver nanoparticles, enhancing antibacterial efficacy significantly compared to traditional solutions. Made from natural silk nanofibers and utilizing proprietary Premotiv nanotechnology, the dressing not only prevents infection but also promotes wound closure. It is designed to be thin and cost-effective, potentially 20% cheaper than competitors' offerings. Nanordica Medical is currently conducting a large-scale clinical trial on diabetic foot ulcers, involving 170 patients across five clinical centers. The company targets healthcare providers, hospitals, and clinics globally, focusing on the growing needs of patients with chronic and severe wounds. Their team consists of experienced scientists and medical professionals, emphasizing a strong foundation in research and clinical practice.

• Employees 16
• Founded 2019